Fourteen patients with extensive-disease non-small-cell lung cancer (E-NSCLC) were treated with oral 4-demethoxydaunorubicin (idarubicin, 4DMDR) at a dosage of 10 mg/m2/day x 5 days every 3 weeks. The median cumulative dose was 110 mg/m2 (range: 50-1,100). Two patients had stable disease for 12 and 56 weeks, respectively, one patient had failed to respond to a doxorubicin hydrochloride (Adriamycin)-containing regimen, and one had had no prior therapy. Twelve of the 14 patients had prior radiotherapy, chemotherapy, or both. Median survival for this heavily treated group was 16 weeks. Myelosuppression was minimal. Nausea and vomiting occurred in 44% of all courses. No cardiac toxicity and no decrease in cardiac ejection fraction was observed. We conclude that 4DMDR is ineffective in heavily treated E-NSCLC patients. However, the drug's activity in untreated patients is unknown. Further study of 4DMDR is indicated in patients who have had no prior chemotherapy or radiotherapy, with routine administration of antiemetic drugs along with pharmacokinetic studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00000421-198912000-00012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combining serum CDK1 with tumor markers for the diagnosis of small cell lung cancer.
Clin Transl Oncol
October 2024
Department of Laboratory Medicine, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Article Synopsis
- The study investigates the role of cell cycle-dependent kinase 1 (CDK1) as a diagnostic tool for small cell lung cancer (SCLC) by comparing serum levels of CDK1 with other markers in different patient groups.
- Results show that CDK1 levels, along with other markers like ProGRP and NSE, are significantly higher in SCLC patients and correlate with cancer progression indicating its potential clinical value.
- The combination of CDK1, ProGRP, and NSE provides the most accurate diagnosis for SCLC, outperforming individual markers and demonstrating high sensitivity and specificity.
Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer.
Respir Med Res
November 2024
Clinical Research Unit, Intergroupe Francophone de Cancérologie Thoracique, 10 rue de la grange batelière, 75009 Paris, France; Pneumology Department, CHU Besançon, 3 boulevard A.Fleming, 25030 Besançon, Cedex, France.
Background: Studies have shown improvement in overall survival with anti-PD1/PD-L1 molecules in combination with cisplatin/carboplatin and etoposide as a first-line treatment for Small Cell Lung Cancer (SCLC). However, first-line efficacy remains limited and well below that observed in Non-Small Cell Lung Cancer (NSCLC). Etoposide may have a detrimental effect on lymphocyte activation, which could explain the limited benefit of immunotherapy in the first line and the lack of benefit in the second line for patients previously exposed to high levels of etoposide.
View Article and Find Full Text PDFHistological sarcomatoid transformation in a lung adenocarcinoma patient following immune checkpoint blockade.
Ther Adv Med Oncol
March 2024
Department of Oncology, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, No. 16766, Jingshi Road, Jinan 250014, China.
Histological transformation is a phenomenon that is well described as one of the causes of tyrosine kinase inhibitor resistance in oncogene-driven non-small-cell lung cancer (NSCLC). The use of immune checkpoint inhibitors (ICIs) as a potential mechanism of acquired resistance to immunotherapy in NSCLC to small-cell lung cancer was also recently found. Here, we report the histological transformation of sarcomatoid carcinoma and metastasis in a lung adenocarcinoma patient without targetable genetic alterations who experienced long-term disease remission after nivolumab therapy.
View Article and Find Full Text PDFSerum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer.
Anticancer Res
February 2024
Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Japan.
Background/aim: Pretreatment serum cytokeratin 19 fragment (CYFRA21-1) level predicts outcomes in patients with non-small cell lung cancer; however, little is known about the clinical value of serum CYFRA21-1 level in patients with small cell lung cancer (SCLC). The aim of this study was to evaluate the prognostic value of pretreatment serum CYFRA21-1 level in patients with extensive disease (ED)-SCLC treated using platinum-doublet chemotherapy.
Patients And Methods: We retrospectively analyzed the pretreatment serum CYFRA21-1 levels of patients with ED-SCLC who were treated using first-line platinum-doublet chemotherapy.
Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilot.
BMJ Open
December 2023
Academic Division of Thoracic Surgery, Royal Brompton and Harefield Hospitals, London, UK
Introduction: Lung cancer is the most common cause of cancer death worldwide and most patients present with extensive disease. One-year survival is improving but remains low (37%) despite novel systemic anti-cancer treatments forming the current standard of care. Although new therapies improve survival, most patients have residual disease after treatment, and little is known on how best to manage it.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!